Troy Ignelzi

Troy joined Rapport in 2023 with more than two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Troy has raised more than $4 billion in capital for life science companies, leading to 8 FDA approved products. Most recently, he was Chief Financial Officer at Karuna Therapeutics, prior to its sale to BMS, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Troy served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals. He has a long track record of experience in the sector, having started out at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Troy served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023, and currently serves on the boards of Abivax (ABVX), Contineum Therapeutics (CNTM) and Harmony Biosciences (HRMY). Troy is also an advisor to Sofinnova Investments and Patients Capital Management.